Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes

Journal of Medicinal Chemistry

Volumn 42, Issue 23, 1999, Pages 4919-4924

  Safavy, Ahmad ^a   Raisch, Kevin P ^c   Khazaeli, M B ^a,b   Buchsbaum, Donald J ^a   Bonner, James A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN RECEPTOR; GASTRIN RECEPTOR; GASTRIN RELEASING PEPTIDE; PACLITAXEL DERIVATIVE; SYNTHETIC PEPTIDE; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; OLIGOPEPTIDES; PACLITAXEL; POLYETHYLENE GLYCOLS; PRODRUGS; RECEPTORS, BOMBESIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 0032727981     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990355x     Document Type: Article

References (34)

1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. Cortes, J. E.; Pazdur, R. Docetaxel. J. Clin. Oncol. 1995, 13, 2643-2655.
3. Miller, K. D.; Sledge, G. W., Jr. Taxanes in the treatment of breast cancer: A prodigy comes of age, Cancer Invest. 1999, 17, 121-136.
4. Arbuck, A.; Blaylock, B. Taxol: Clinical results and current issues in development. In Taxol Science and Applications; Suffness, M., Ed.; CRC: Boca Raton, FL, 1995; pp 379-415.
5. Suffness, M. Taxol: from discovery to therapeutic use. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1993; pp 305-314.
6. Rose, W. C. Taxol: A review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs 1992, 3, 311-321.
7. Tishler, R. B.; Geard, C. R.; Hall, E. J.; Schiff, P. B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992, 52, 3495-3497.
8. 90Y-LYM-1 for Raji lymphoma xenografts. Cancer Biother. Radiopharm. 1998, 13, 351-361.
9. Distefano, M.; Scambia, G.; Ferlini, C.; Gaggini, C.; De Vincenzo, R.; Riva, A.; Bombardelli, E.; Ojima, I.; Fattorossi, A.; Panici, P. B.; Mancuso, S. Anti-proliferative activity of a new class of taxanes (14-beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer 1997, 72, 844-850.
10. Dorr, R. T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 1994, 28, S11-S14.
11. Sharma, A.; Mayhew, E.; Bolcsak, L.; Cavanaugh, C.; Harmon, P.; Janoff, A.; Bernacki, R. J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 1997, 71, 103-107.
12. Roland, P. Y.; Barnes, M. N.; Niwas, S.; Robertson, M. W.; Alvarez, R.; Austin, J. M.; Kilgore, L. C.; Partridge, E. E. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Gynecol. Oncol. 1998, 68, 178-182.
13. Preston, N. J. Paclitaxel (Taxol): A guide to administration. Eur. J. Cancer Care 1996, 5, 147-152.
14. Hajek, R.; Vorlicek, J.; Slavik, M. Paclitaxel (Taxol): A review of its antitumor activity in clinical studies. Minireview. Neoplasma 1996, 43, 141-154.
15. Postma, T. J.; Vermorken, J. B.; Liefting, A. J.; Pinedo, H. M.; Heimans, J. J. Paclitaxel-induced neuropathy. Ann. Oncol. 1995, 6, 489-494.
16. Maier-Lenz, H.; Hauns, B.; Haering, B.; Koetting, J.; Mross, K.; Unger, C.; Bauknecht, T.; du Bois, A.; Meerpohl, H. G.; Hollaender, N.; Diergarten, K. Phase I study of paclitaxel administered as a 1-hour infusion: Toxicity and pharmacokinetics. Semin. Oncol. 1991, 24, S19-16-S19-19.
17. Goodwin, D. A. Stategies for antibody targeting. Antib. Immunoconj. Radiopharm. 1991, 4, 427-434.
18. Kohler, G. M. C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
19. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279, 377-380.
20. Hoffman, T. J.; Sieckman, G. L.; Volkert, W. A. Targeting small cell lung cancer using iodinated peptide analogues. J. Labeled Comp. Radiopharm. 1995, 37, 321-323.
21. Chang, A Y.; Kim, K.; Click, J.; Anderson, T.; Karp, D.; Johnson, D. Phase II study of taxol, merbarone, and piroxantrone in stage IV nonsmall-cell lung cancer: The Eastern Cooperative Oncology Group Results. J. Natl. Cancer Inst. 1993, 85, 388-394.
22. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
23. Li, C.; Yu, D.; Inoue, T.; Yang, D. J.; Milas, L.; Hunter, N. R.; Kim, E. E.; Wallace, S. Synthesis and evaluation of water-soluble poly(ethylene glycol)-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 1996, 7, 642-648.
24. Greenwald, E.; Pendri, A.; Bolikal, D. Highly water soluble-taxol derivatives: 7-poly(ethylene glycol) carbamates and carbonates. J. Org. Chem. 1996, 60, 331-336.
25. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 1996, 39, 424-431.
26. Pendri, A.; Conover, C. D.; Greenwald, R. B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anticancer Drug Des. 1998, 13, 387-395.
27. Safavy, A. Unpublished results.
28. Nicolaou, K. C.; Riemer, C.; Kerr, M. A.; Rideout, D.; Wrasidlo, W. Design, synthesis and biological activity of protaxols. Nature 1993, 364, 464-466.
29. Deutsch, H.; Glinski, J.; Hernandez, M.; Haugwitz, R.; Narayanan, V.; Suffness, M.; Zalkow, L. Synthesis of congeners and prodrugs: Water soluable prodrugs of taxol with potent antitumor activity. J. Med. Chem. 1989, 32, 788-792.
30. Zalipsky, S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjugate Chem. 1995, 6, 150-165.
31. Battey, J. F.; Way, J. M.; Corjay, M. H.; Shapira, H.; Kusano, K.; Harkins, R.; Wu, J. M.; Slattery, T.; Mann, E.; Feldman, R. I. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 395-399.
32. Safavy, A.; Khazaeli, M. B.; Qin, H.; Buchsbaum, D. J. Synthesis of bombesin analogues for radiolabeling with Rhenium-188. Cancer (Suppl). 1997, 80, 2354-2359.
33. Moody, T. W.; Zia, F.; Venugopal, R.; Fagarasan, M.; Oie, H.; Hu, V. GRP receptors are present in non small cell lung cancer cells. J. Cell. Biochem. Suppl. 1998, 24, 247-256.
34. a-fluorenylmethyloxycarboxylamino acids emplified by synthesis of dihydrosomatostatin. Int. J. Pept. Protein Res. 1978, 11, 246-249.